Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 9/20 | 0.70 |
| ▸ | PYGM | P11217 | 3/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18573991 | 1.00 | TK2 (0.70) | TK2PYGMP2RY2SLC28A1SLC28A2 | |
| SCHEMBL14946349 | 1.00 | TK2 (0.70) | TK2PYGMP2RY2SLC28A1SLC28A2 | |
| SCHEMBL14916547 | 1.00 | TK2 (0.70) | TK2PYGMP2RY2SLC28A1SLC28A2 | |
| SCHEMBL6888284 | 1.00 | TK2 (0.70) | TK2PYGMP2RY2SLC28A1SLC28A2 | |
| SCHEMBL14929316 | 1.00 | TK2 (0.70) | TK2PYGMP2RY2SLC28A1SLC28A2 | |
| SCHEMBL2575473 | 1.00 | TK2 (0.70) | TK2PYGMP2RY2SLC28A1SLC28A2 | |
| Phosphoric Acid SCHEMBL21465238 | 0.96 | TK2 (0.65) | TK2PYGMP2RY2 | |
| SCHEMBL2582359 | 0.92 | TK2 (0.61) | TK2PYGM | |
| SCHEMBL2582357 | 0.92 | TK2 (0.61) | TK2PYGM | |
| SCHEMBL3071199 | 0.91 | TK2 (0.58) | TK2PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1850 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250277223-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES | IMCYSE SA (BE) | 2025-09-04 | — | — | US | claimed |
| EP-4598935-A2 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250161488-A1 | THERAPEUTIC mRNA | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-22 | — | — | US | claimed |
| EP-4408886-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2024-08-07 | — | — | EP | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2023052531-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2023-04-06 | — | — | WO | claimed |
| EP-4126039-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION | BioNTech SE (DE) | 2023-02-08 | — | — | EP | claimed |
| WO-2022248525-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES | IMCYSE SA (BE) | 2022-12-01 | — | — | WO | claimed |
| WO-2021198258-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION | BioNTech SE (DE) | 2021-10-07 | — | — | WO | claimed |
| WO-2021197589-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION | BioNTech SE (DE) | 2021-10-07 | — | — | WO | claimed |
| US-20200061166-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BioNTech SE (DE) | 2020-02-27 | — | — | US | claimed |
| EP-3609529-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BioNTech RNA Pharmaceuticals GmbH (DE) | 2020-02-19 | — | — | EP | claimed |
| CN-110719787-A | RNA for treating autoimmune diseases | 生物技术RNA制药有限公司 | 2020-01-21 | — | — | CN | claimed |
| WO-2018189193-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2018-10-18 | — | — | WO | claimed |
| WO-2018188730-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2018-10-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | RNGTT, RNMT, NSUN3 | TK2 1051/4885PYGM 689/4885P2RY2 577/4885 |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | CD274, PDCD1LG2, PDCD1 | TK2 2839/4885PYGM 2384/4885P2RY2 4405/4885 |
| US-20200061166-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | NSUN3, RBM28, TRDMT1 | TK2 2217/4885PYGM 4547/4885P2RY2 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.